Search Results
Jul 10, 2026, 22:00 ET Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
Erasca, Inc. (NasdaqGS: ERAS) ("Erasca" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 14, 2025 and April 26, 2026, inclusive
More news about: ClaimsFiler
Jul 10, 2026, 14:22 ET Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ERAS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ERASCA, INC. (ERAS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 10, 2026 (LEAD PLAINTIFF DEADLINE)
More news about: Law Offices of Howard G. Smith
Jul 10, 2026, 08:00 ET New Era's 2026 MLB All-Star Collection Honors America's 250th Anniversary
Classic has been one of America's premier sports events, showcasing the game's greatest talent and demonstrating the uniting power of baseball. New Era's 2026 MLB All-Star Collection honors this beloved tradition with a collection designed to be cherished long after the final pitch is thrown. The collection
More news about: New Era Cap LLC
Jul 09, 2026, 17:22 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed to Grade
More news about: Pomerantz LLP
Jul 09, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed's RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has "in-licensed one
More news about: Hagens Berman Sobol Shapiro LLP
Jul 09, 2026, 06:05 ET ERAS DEADLINE NOTICE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015 and other product candidates were based on
More news about: Robbins Geller Rudman & Dowd LLP
Jul 08, 2026, 12:07 ET Federal Court Upholds New Era ADR's Updated Procedures in Live Nation Litigation
Ticketmaster. After undertaking what it describes as a "fresh analysis" of New Era's revised arbitration procedures, the Court concluded that those procedures are enforceable. The opinion is among the first to evaluate New Era's revised arbitration procedures following changes made in response to earlier
More news about: New Era ADR
Jul 08, 2026, 10:11 ET Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
the market price of ERAS common stock was artificially inflated by statements promoting ERAS-0015's alleged superiority over RevMed's RMC-6236. The complaint asserts the following sequence quantifies investor harm:Erasca repeatedly claimed ERAS-0015 achieved "comparable
More news about: Levi & Korsinsky, LLP
Jul 07, 2026, 20:48 ET Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS
compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed's RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has "in-licensed one
More news about: Hagens Berman Sobol Shapiro LLP
Jul 07, 2026, 18:51 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared
More news about: THE ROSEN LAW FIRM, P. A.
Jul 07, 2026, 15:16 ET Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ERAS) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 07, 2026, 04:58 ET Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS
ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ERAS during the class period listed are encouraged
More news about: DJS Law Group LLP
Jul 07, 2026, 04:58 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
statements to the market. Erasca's Preclinical data on ERAS-0015 was built on an improper comparison to Revolution Medicines, Inc., which placed it at risk of violating patent protections. The Company lacked basis for its optimistic statements on ERAS-0015. Based on these facts, the Company's public statements
More news about: The Schall Law Firm
Jul 03, 2026, 22:00 ET Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Erasca, Inc. ("Erasca" or the "Company") (NasdaqGS: ERAS) of a class action securities lawsuit.
More news about: Kahn Swick & Foti, LLC
Jul 02, 2026, 20:04 ET Chiquita Celebrates America's 250th Anniversary with New Brand Video Featuring Miss Chiquita
together.Miss Chiquita Guides Viewers Through America's StoryIn the video, Miss Chiquita leads viewers through a journey across defining eras of American life. Moving seamlessly through time, she connects historical events with everyday scenes that remain familiar through the years.The
More news about: Chiquita Brands International, Inc.
Jul 02, 2026, 17:47 ET ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Investigating Allegations that Erasca, Inc. (ERAS) Failed to Disclose it Was at Risk of Violating Patent and Trade Secret ProtectionsAccording to the complaint, during the class period, defendants failed to disclose material facts, including that: (1) ERAS-0015's preclinical data was based on improper
More news about: Robbins LLP
Jul 02, 2026, 09:00 ET ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed's RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has "in-licensed one
More news about: Hagens Berman Sobol Shapiro LLP
Jul 01, 2026, 22:12 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared
More news about: THE ROSEN LAW FIRM, P. A.
Jul 01, 2026, 12:29 ET Real Estate Expert Phil Frye of Newark Explores Move-In Ready Homes for HelloNation
with one's personal taste can be unrealistic. While some properties may be recently renovated, many others will reflect design choices from earlier eras. Phil Frye advises buyers to approach Newark real estate with flexibility. A few small home upgrades—such as new paint, lighting fixtures, or landscaping—can
More news about: HelloNation
Jul 01, 2026, 10:07 ET ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
filed by August 10, 2026.Frequently Asked Questions About the ERAS LawsuitQ: What is the ERAS class action lawsuit about? A: A securities class action has been filed against Erasca, Inc. (NASDAQ: ERAS) alleging materially false and misleading statements between January 14,
More news about: Levi & Korsinsky, LLP
Jul 01, 2026, 06:00 ET INVESTOR ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015 and other product candidates were based
More news about: Robbins Geller Rudman & Dowd LLP
Jun 30, 2026, 12:00 ET Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ERAS).
More news about: Glancy Prongay Wolke & Rotter LLP
Jun 29, 2026, 16:15 ET Your Travel Day Super Hero Has Arrived: CLEAR Teams Up with Marvel Animation's "X-Men '97" Season 2 to Help Members Win the Day of Travel
a 99% on Rotten Tomatoes as of today."X-Men '97" Season 2 continues with the heroic mutant team of X-Men, divided and thrown across different eras in time as they struggle to navigate their return home. Meanwhile, back in the 1990s, suspicious foes and new strains of mutant intolerance are on the
More news about: CLEAR
Jun 29, 2026, 15:36 ET Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed's RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has "in-licensed one
More news about: Hagens Berman Sobol Shapiro LLP
Jun 26, 2026, 22:00 ET Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
Erasca, Inc. (NasdaqGS: ERAS) ("Erasca" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 14, 2025 and April 26, 2026, inclusive
More news about: ClaimsFiler